Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Sleep Duration Associated With Variations In Levels Of Inflammatory Markers In Women
A study in the July 1 issue of the journal SLEEP demonstrates that levels of inflammatory markers varied significantly with self-reported sleep duration in women but not men.
generic viagra online
World Leaders Must Take Action To Support Commitments To Lower Maternal Mortality, Opinion Piece Says
"I stood up and applauded for women everywhere when I heard the news" that the United Nations Human Rights Council, including the U.S., "recognized maternal death as a human rights issue," CARE President and CEO Helene Gayle writes in an Atlanta Journal-Constitution opinion piece. Gayle writes that governments for the past 15 years "have failed to meet the commitments made and targets set to reduce the more than half a million maternal deaths every year."According to Gayle, preventing maternal death "requires three well-coordinated actions: sustain political leadership, secure adequate res and strengthen health systems." She adds that the resolution "is a positive step" but that it is "only effective if it translates into action." She continues, "It"s great to see the Obama administration places women and girls high on the agenda," adding that many members of Congress also support these issues.Reducing maternal mortality "requires significant res," Gayle writes. She adds, "To be blunt, an estimated global commitment of $39 billion over 10 years is needed to make significant progress." Such a commitment would be "an investment in women, their families and the economic productivity of nations," according to Gayle."The cost of not investing is far greater," Gayle continues. She notes that women "do two-thirds of the world"s work and produce nearly 60% of the world"s food." In addition, "children who lose their mothers are 10 times more likely to die in childhood than children with mothers," and maternal and newborn deaths "represent an estimated annual loss of $15.5 billion in productivity," according to Gayle. "Clearly, other development goals cannot be met without healthy mothers," she adds.She continues that the "most tragic and infuriating point" is that the "death of a woman in childbirth is one of the most inexcusable deaths on earth." Because high maternal mortality is a "barometer of weak health systems, often reflecting the low status of women," strengthening health systems to improve maternal health will therefore enable the system to "address other health needs," Gayle writes. She adds that countries such as Bangladesh, Ethiopia and Peru have improved mortality rates "through four lifesaving programs: family planning, skilled and culturally sensitive care during pregnancy and childbirth, emergency care for complications and postpartum care."Gayle writes, "The U.S. can spearhead a comprehensive maternal health action plan and, by doing so, set an example for world leaders to join and invest in." She concludes, "The actions we take now can make maternal death a problem of the past and not one of our children"s future" (Gayle, Atlanta Journal-Constitution, 7/10). Drugshop to buy zoloft online and other pills.
News of the day
Low Prevalence Of HPV Infection May Be Tied To Poor Prognosis For Blacks With Head And Neck Cancer
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer have found that head and neck cancer patients who test positive for the human papillomavirus (HPV) have much better survival rates than patients who don"t have the virus, according to a new study in the journal Cancer Prevention Research. The researchers also discovered that blacks in the study had a very low rate of HPV infection, and consequently worse survival, which may explain why African-American patients traditionally have had a poor prognosis for head and neck cancer.
Cardiovascular

Cancer Vaccines Led To Long-Term Survival For Patients With Metastatic Melanoma, Study Shows

Hoag Memorial Hospital Presbyterian announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients" own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies. The study entitled "Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Anti-Tumor Vaccines in Patients with Metastatic Melanoma," was published in the June 2009 issue of Cancer Biotherapy and Radiopharmaceuticals and was sponsored by Hoag Hospital Foundation. "There is continued interest in developing new therapies for melanoma patients with recurrent or distant metastatic disease at the time of diagnosis because there are no systemic therapies that can be relied upon to cure them," said Robert O. Dillman, M.D., F.A.C.P., executive medical and scientific director at the Hoag Cancer Center and lead investigator for the study. "Patients with metastatic melanoma are at high risk for additional metastases and death." During the study, 54 patients with regionally recurrent or distant metastatic melanoma were injected with a vaccine that included each patient"s own immune cells (dendritic cells) and 500 micrograms of granulocyte-colony stimulating factor (GM-CSF), an immune stimulator, three times a week and then monthly for five months for a total of up to eight injections. The patient"s dendritic cells were obtained from their peripheral blood and mixed with a cell culture of the patient"s own melanoma cells that had been self-renewing and proliferating in the laboratory. The patient-specific vaccine is designed to stimulate the patient"s immune system to react against tumor stem cells or early progenitor cells that can create new depots of cancer throughout the body. Data showed that the projected five-year survival rate is 54% at a median follow up of 4.5 years (range 2.4 to 7.4) for the 30 surviving patients. Although not a direct comparison, the results are superior to those observed following vaccination with irradiated tumor cells in 48 melanoma patients in a previous trial (64 vs. 31 months, p=.016). Eight patients in the dendritic cell vaccine study experienced remarkable long-term, progression-free survival after completing the vaccine therapy, even though they had widely metastatic disease and/or repeated appearance of new metastases despite various therapies. The vaccine treatment was well-tolerated, with most patients experiencing mild skin irritation and redness at the injection site. "The one-year and projected five-year survival rates of 85% and 54%, respectively, are remarkable for melanoma patients with documented metastatic disease," said Dr. Dillman. "This study is extremely encouraging and shows the potential these types of personalized cancer vaccines have for patients diagnosed with metastatic melanoma." Kelly Smith Hoag Memorial Hospital Presbyterian


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009